Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB1521 : JHOS-2  update : 2022/05/30
CommentHuman cell line derived from ovarian serous adenocarcinoma. Said CA125 and CA15-3 producing. Application consideration
Comment from the depositor
Terms and conditionsA prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
Remarks
approver's address
×
English
Address
Contact Us
cellbank.brc@riken.jp
RIKEN, BioResource Research Center
Cell Engineering Division
Dr.Cell Bank (ISHIKAWA Hiroshi)
Fax. +81-29-836-9130
Order Form Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Ishikawa, Hiroshi
Originator Ishikawa, H. & Yasuda, M.
Year of deposit 1999
Animal human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 45 years
Tissue ovary
Disease name serous adenocarcinoma of ovary
Metastastatic ability Yes
Metastatsd tissue lymph node
Classification cancer
Year of origin 1997
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_4647
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives DMEM/HamF12 + 10% FBS + 0.1mM NEAA
Antibiotics Free
Passage method (0.05% Trypsin + 0.02% EDTA) or (0.25% Trypsin + 0.04% EDTA)
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : once/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
Chromosome mode 74-83(50) : /76(7),77(6),78(8),79(9),80(4),81(5)/
STR(human) OK
Images
deposit info
lot info
Reference information Reference 1
User's Publication 23


To topTop
Reference
2405  Yamada K, Tachibana T, Hashimoto H, Suzuki K, Yanagida S, Endoh H, Kimura E, Yasuda M, Tanaka T, Ishikawa H  Establishment and characterization of cell lines derived from serous adenocarcinoma (JHOS-2) and clear cell adenocarcinoma (JHOC-5, JHOC-6) of human ovary.  Hum Cell  1999  12:131-8  PubMed ID: 10695020  

To topTop
User's Publication
20521  Machino H, Kaneko S, Komatsu M, Ikawa N, Asada K, Nakato R, Shozu K, Dozen A, Sone K, Yoshida H, Kato T, Oda K, Osuga Y, Fujii T, von Keudell G, Saloura V, Hamamoto R.  The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma.  Commun Biol  2022  5(1):39  PubMed ID: 35017636   DOI: 10.1038/s42003-021-02992-4
20800  Fu L, Zhang D, Yi N, Cao Y, Wei Y, Wang W, Li L.  Circular RNA circPBX3 promotes cisplatin resistance of ovarian cancer cells via interacting with IGF2BP2 to stabilize ATP7A mRNA expression.  Hum Cell  2022    PubMed ID: 35907138   DOI: 10.1007/s13577-022-00748-8
20211  Oyama Y, Shigeta S, Tokunaga H, Tsuji K, Ishibashi M, Shibuya Y, Shimada M, Yasuda J, Yaegashi N.  CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.  PLoS One  2021  16(6):e0251079  PubMed ID: 34161330   DOI: 10.1371/journal.pone.0251079
13066  Álvarez-Quilón A, Wojtaszek JL, Mathieu MC, Patel T, Appel CD, Hustedt N, Rossi SE, Wallace BD, Setiaputra D, Adam S, Ohashi Y, Melo H, Cho T, Gervais C, Muñoz IM, Grazzini E, Young JTF, Rouse J, Zinda M, Williams RS, Durocher D.  Endogenous DNA 3' Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 Nuclease.  Mol Cell  2020    PubMed ID: 32516598   DOI: 10.1016/j.molcel.2020.05.021
13262  Escalona RM, Bilandzic M, Western P, Kadife E, Kannourakis G, Findlay JK, Ahmed N.  TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.  BMC Cancer  2020    PubMed ID: 33023532   DOI: 10.1186/s12885-020-07274-6
13385  Neggers JE, Paolella BR, Asfaw A, Rothberg MV, Skipper TA, Yang A, Kalekar RL, Krill-Burger JM, Dharia NV, Kugener G, Kalfon J, Yuan C, Dumont N, Gonzalez A, Abdusamad M, Li YY, Spurr LF, Wu WW, Durbin AD, Wolpin BM, Piccioni F, Root DE, Boehm JS, Cherniack AD, Tsherniak A, Hong AL, Hahn WC, Stegmaier K, Golub TR, Vazquez F, Aguirre AJ.  Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q.  Cell Rep  2020    PubMed ID: 33326793   DOI: 10.1016/j.celrep.2020.108493
13387  Wada M, Kukita A, Sone K, Hamamoto R, Kaneko S, Komatsu M, Takahashi Y, Inoue F, Kojima M, Honjoh H, Taguchi A, Kashiyama T, Miyamoto Y, Tanikawa M, Tsuruga T, Mori-Uchino M, Wada-Hiraike O, Osuga Y, Fujii T.  Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.  Biomolecules  2020    PubMed ID: 33339442   DOI: 10.3390/biom10121686
13700  Kudo K, Nomura M, Sakamoto Y, Ito S, Morita M, Kawai M, Yamashita Y, Ito K, Yamada H, Shima H, Yaegashi N, Tanuma N.  Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer  FEBS Lett  2020  594(9):1379-1388  PubMed ID: 31950503   DOI: 10.1002/1873-3468.13736
11501  Kukita A, Sone K, Oda K, Hamamoto R, Kaneko S, Komatsu M, Wada M, Honjoh H, Kawata Y, Kojima M, Oki S, Sato M, Asada K, Taguchi A, Miyasaka A, Tanikawa M, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T.  Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.  Biochem. Biophys. Res. Commun.  2019    PubMed ID: 30955858   DOI: 10.1016/j.bbrc.2019.03.155
11511  Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, Santos R, Rao Y, Sassi F, Pinnelli M, Ansari R, Harper S, Jackson DA, McRae R, Pooley R, Wilkinson P, van der Meer D, Dow D, Buser-Doepner C, Bertotti A, Trusolino L, Stronach EA, Saez-Rodriguez J, Yusa K, Garnett MJ.  Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.  Nature  2019    PubMed ID: 30971826   DOI: 10.1038/s41586-019-1103-9
13420  Hamedi, Bahareh  Anti-cancer effects of n-3 long-chain polyunsaturated fatty acids (LCPUFA) on ovarian cancer growth in vitro and in vivo    2019      DOI: 10.7939/r3-44r2-2q82
10833  Taki M, Abiko K, Baba T, Hamanishi J, Yamaguchi K, Murakami R, Yamanoi K, Horikawa N, Hosoe Y, Nakamura E, Sugiyama A, Mandai M, Konishi I, Matsumura N.  Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation.  Nat Commun  2018  9:1685  PubMed ID: 29703902   DOI: 10.1038/s41467-018-03966-7
10676  Kollmorgen G, Palme K, Seidl A, Scheiblich S, Birzele F, Wilson S, Clemens C, Voss E, Kaufmann M, Hirzel K, Rieder N, Krippendorff BF, Herting F, Niederfellner G.  A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer.  Sci Rep  2017  7:18086  PubMed ID: 29273809   DOI: 10.1038/s41598-017-17329-7
9659  Elayne Chan-Penebre, Kelli Armstrong, Allison Drew, Alexandra R Grassian, Igor Feldman, Sarah K Knutson, Kristy Kuplast-Barr, Maria Roche, John Campbell, Peter Ho, Robert A Copeland, Richard Chesworth, Jesse J Smith, Heike Keilhack, Scott A Ribich  Selective Killing of SMARCA2- And SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models  Mol Cancer Ther   2017  16(5):850-860  PubMed ID: 28292935   DOI: 10.1158/1535-7163.MCT-16-0678
14252  Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S.  Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification  Int J Oncol  2017  50(1):129-140.  PubMed ID: 27922671   DOI: 10.3892/ijo.2016.3786
15031  Takaya A, Peng WX, Ishino K, Kudo M, Yamamoto T, Wada R, Takeshita T, Naito Z.  Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma  Int J Oncol  2015  46(4):1573-81  PubMed ID: 25633807   DOI: 10.3892/ijo.2015.2858
9658  Tomoko Kashiyama, Katsutoshi Oda, Yuji Ikeda, Yoshinobu Shiose, Yasuhide Hirota, Kanako Inaba, Chinami Makii, Reiko Kurikawa, Aki Miyasaka, Takahiro Koso, Tomohiko Fukuda, Michihiro Tanikawa, Keiko Shoji, Kenbun Sone, Takahide Arimoto, Osamu Wada-Hiraike, Kei Kawana, Shunsuke Nakagawa, Koichi Matsuda, Frank McCormick, Hiroyuki Aburatani, Tetsu Yano, Yutaka Osuga, Tomoyuki Fujii  Antitumor Activity and Induction of TP53-dependent Apoptosis Toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423  PLoS One  2014  9(2):e87220  PubMed ID: 24504419   DOI: 10.1371/journal.pone.0087220
15801  Nishio H, Yaguchi T, Sugiyama J, Sumimoto H, Umezawa K, Iwata T, Susumu N, Fujii T, Kawamura N, Kobayashi A, Park J, Aoki D, Kawakami Y.  Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor  Br J Cancer   2014  110(12):2965-74  PubMed ID: 24867687   DOI: 10.1038/bjc.2014.251
9669  Ikue Nakayama, Masahiko Shibazaki, Akiko Yashima-Abo, Fumiharu Miura, Toru Sugiyama, Tomoyuki Masuda, Chihaya Maesawa  Loss of HOXD10 Expression Induced by Upregulation of miR-10b Accelerates the Migration and Invasion Activities of Ovarian Cancer Cells  Int J Oncol  2013  43(1):63-71  PubMed ID: 23670532   DOI: 10.3892/ijo.2013.1935
15560  Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, Hayashi S, Sasano H, Yaegashi N.  Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma.  Cancer Sci  2008  99:2365-72  PubMed ID: 19032364   DOI: 10.1111/j.1349-7006.2008.00988.x
2934  Akahira, Jun-ichi, Sugihashi, Youko, Suzuki, Takashi, Ito, Kiyoshi, Niikura, Hitoshi, Moriya, Takuya, Nitta, Makoto, Okamura, Hitoshi, Inoue, Satoshi, Sasano, Hironobu, Okamura, Kunihiro, Yaegashi, Nobuo  Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation.  Clin Cancer Res  2004  10:2687-93  PubMed ID: 15102672   DOI: 10.1158/1078-0432.ccr-03-0510
3094  Kaneda, Atsushi, Wakazono, Kuniko, Tsukamoto, Tetsuya, Watanabe, Naoko, Yagi, Yukiko, Tatematsu, Masae, Kaminishi, Michio, Sugimura, Takashi, Ushijima, Toshikazu  Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers.  Cancer Res  2004  64:6410-5  PubMed ID: 15374948   DOI: 10.1158/0008-5472.CAN-04-1543
3796  Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, Takamoto S, Murakami Y.  Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines.  Int J Cancer  2003  107(1):53-9  PubMed ID: 12925956   DOI: 10.1002/ijc.11348


Back Back Return Top Page